Some studies suggest that they help reduce the risk of heart and kidney disease, support liver health (especially in people with fatty liver disease), and may delay the progression of diabetic kidney complications
The aim of this article is to discuss CVOTs involving GLP-1 receptor agonists and their impact on cardiovascular risk
If you look across the randomized trials, the adverse event rates to me are fairly alarming
Moreover, the SGLT2i empagliflozin prevented the increase in inflammation and fibrosis induced by high glucose by blocking glucose transport, without inducing a compensatory increase in SGLT1/GLUT2 expression in the human kidney proximal tubular cell line (HK2 cells) [92]
A person who begins skipping meals while taking a GLP-1 medication may receive a very different response than a person who begins skipping meals without one, even if the nutritional consequences are identical
39 Historically, this was observed to be associated with lower all-cause and CV mortality, 40 although the impact on risk of incident HF was not specifically examined